Shots:

• The company to initiate the clinical trial assessing the safety and efficacy of its COVID-19 drug based on the Grifols’ immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal Abs from plasma donors who have recovered from the disease
• The study is expected to be initiated in Feb’2021. The treatment will be administered in primary care centers in people who test positive for COVID-19- avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination
• The Grifols immunoglobulin Gamunex-C (IV- IM- SC) has proven to be safe and efficacious in the prevention of diverse infectious diseases in an immunocompromised patient

 ­ Ref: PRNewswire | Image: Yicai Global